Announcement PDF +61 (03) 9482 3940 157 Heidelberg Rd, Northcote, VIC 3070 www.renerve.com.au ASX Announcement 19 December 2025 ReNerve appoints Maja McGuire as Non-Executive Chair ReNerve Limited (ASX, "ReNerve" or "the Company"), an Australian biotechnology company developing innova ve products for peripheral nerve injury ("PNI") repair, is pleased to announce the appointment of Ms Maja McGuire as Non-Execu ve Chair of the Company’s Board of Directors, effec ve immediately. Ms McGuire was appointed to the ReNerve Board as a Non-Execu ve Director and interim chair on 4 December 2025 as part of the Company’s Board renewal process. Her appointment as Chair reflects the Board’s focus on strengthening governance, strategic oversight and leadership as ReNerve con nues to progress its commercial and development programs. Ms McGuire brings more than 15 years’ experience across board and senior management roles, including as a Chair and Non-Execu ve Director of ASX-listed companies. She has extensive experience in corporate strategy, governance and listed-company advisory roles, with a background as General Counsel and Company Secretary in the medical device and life sciences sectors. Ms McGuire currently serves as Non-Execu ve Chair of TechGen Metals and as a Non-Execu ve Director of several ASX-listed companies. Ms McGuire said she was “delighted to be joining ReNerve at a me when it is looking at strong growth and further development of its innova ve technologies that makes significant quality of life interven ons to pa ents suffering peripheral nerve damage” “We are very pleased to appoint Maja as Non-Execu ve Chair of ReNerve. Her experience in governance, corporate strategy and medical device companies will be highly valuable as the Company con nues to execute on its commercial strategy and advance its development programs.” said CEO Dr Julian Chick. - ENDS - This announcement has been approved for release by the Company’s Board of Directors. For further informa on and enquiries, please contact: Dr Julian Chick CEO & Managing Director ReNerve Ltd +61 (03) 9482 3940 info@renerve.com.au Ma hew Wright Investor & Media Rela ons NWR Communica ons +61 (0) 451 896 420 ma @nwrcommunica ons.com.au 2 | P a g e About ReNerve Limited (ASX:RNV) ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolu onised peripheral nerve surgery with its innova ve, ready-to-use solu ons for peripheral nerve injuries (PNI). Our scien fically backed products are delivering measurably be er outcomes for pa ents worldwide. Proven Clinical Success ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a drama c difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that pa ents treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a sta s cally significant improvement that's changing lives. Comprehensive Product Por olio ReNerve is advancing a complete suite of nerve repair solu ons:  NervAlign® Nerve Cuff – Our bioabsorbable protec ve wrap, naturally absorbed within six months of surgery.  Deep Dermal ssue product -- A unique deep dermal product used in the repair of reconstruc ve and cosme c surgical cases.  Amnio c ssue product ranges -- Three amnio c ssue product ranges used to aid the healing of wounds.  NervAlign® Nerve Conduit Range – Next-genera on nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.  NervAlign® Nerve Guide Matrix – a customised and ready-to-use alterna ve to exis ng nerve gra s, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for pa ents to undergo addi onal sural nerve harves ng.  NervAlign® Bionic Nerve – Next-genera on combina on technology for the most challenging nerve repairs. Market Leadership and Growth With demonstrated market trac on since the Company’s 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin, scalable products are posi oning us as the go-to solu on for surgeons seeking superior pa ent outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.1 1 Global Nerve Repair Biomaterials Market Research Report (2020 – 2031) 3 | P a g e Vision and Values We're not just developing medical devices – we're engineering hope. By crea ng the ideal healing environment for nerve repair and regenera on, ReNerve bridges cri cal gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effec ve solu ons represent the future of peripheral nerve surgery.